Ventris Medical announced the successful commercialization and clinical integration of Backpack® Osteoinductive Bone Graft, its porous biologic scaffold and bone graft containment technology, in use in 11 healthcare systems nationwide.
Backpack is designed for spinal fusion procedures and represents a new class of biomaterials intended to support cell proliferation and bone formation. Ventris Medical offers Backpack in two versions: Backpack + Allocell® AF, which incorporates 100% human tissue-derived osteoinductive bone fibers in a proprietary biologic pouch, and Backpack AMP, a synthetic option using the company’s patented Amplify® granule technology.
“Reaching meaningful adoption across these systems is an important milestone for Ventris Medical and a strong validation of Backpack® in real-world clinical settings,” said Russell Cook, CEO of Ventris Medical. “We’re proud to support surgeons and care teams with a first-of-its-kind graft containment platform that advances bone graft technology available today.”
Ventris Medical previously announced U.S. FDA 510(k) clearance for Backpack (Porous Biologic Scaffold, K240765) and has also reported an additional 510(k) clearance for Backpack for use in the intervertebral disc space. Building on these regulatory milestones, the company is now focused on expanding access and supporting broader clinical adoption across the United States.
Ventris Medical announced the successful commercialization and clinical integration of Backpack® Osteoinductive Bone Graft, its porous biologic scaffold and bone graft containment technology, in use in 11 healthcare systems nationwide.
Backpack is designed for spinal fusion procedures and represents a new class of biomaterials intended to...
Ventris Medical announced the successful commercialization and clinical integration of Backpack® Osteoinductive Bone Graft, its porous biologic scaffold and bone graft containment technology, in use in 11 healthcare systems nationwide.
Backpack is designed for spinal fusion procedures and represents a new class of biomaterials intended to support cell proliferation and bone formation. Ventris Medical offers Backpack in two versions: Backpack + Allocell® AF, which incorporates 100% human tissue-derived osteoinductive bone fibers in a proprietary biologic pouch, and Backpack AMP, a synthetic option using the company’s patented Amplify® granule technology.
“Reaching meaningful adoption across these systems is an important milestone for Ventris Medical and a strong validation of Backpack® in real-world clinical settings,” said Russell Cook, CEO of Ventris Medical. “We’re proud to support surgeons and care teams with a first-of-its-kind graft containment platform that advances bone graft technology available today.”
Ventris Medical previously announced U.S. FDA 510(k) clearance for Backpack (Porous Biologic Scaffold, K240765) and has also reported an additional 510(k) clearance for Backpack for use in the intervertebral disc space. Building on these regulatory milestones, the company is now focused on expanding access and supporting broader clinical adoption across the United States.
Copy to clipboard 
